Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Quantitative Modeling Of Tumor Dynamics And Development Of Drug Resistance In Non-small Cell Lung Cancer Patients Treated With Erlotinib

Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib

Anyue Yin1, G D Marijn Veerman2, Johan G C van Hasselt3

  • 1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

CPT: Pharmacometrics & Systems Pharmacology
|February 20, 2024

Related Experiment Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K
Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

7.5K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

View abstract on PubMed

Summary
This summary is machine-generated.

Understanding erlotinib resistance in non-small cell lung cancer is key. Baseline circulating tumor DNA (ctDNA) levels, particularly EGFR mutations, correlate with tumor growth, aiding treatment optimization.

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Oncology
  • Molecular Biology

Background:

  • Treatment resistance is a major challenge in optimizing anticancer therapies.
  • Erlotinib is a targeted therapy for non-small cell lung cancer (NSCLC).
  • Understanding tumor dynamics and resistance mechanisms is crucial for improving treatment efficacy.

Purpose of the Study:

  • To characterize tumor dynamics and drug resistance development in NSCLC patients treated with erlotinib.
  • To investigate the relationship between baseline circulating tumor DNA (ctDNA) and tumor dynamics.
  • To explore the predictive potential of ctDNA for anticancer treatment response.

Main Methods:

  • Developed a two-compartment population pharmacokinetic (PK) model for erlotinib.
  • Integrated PK data with tumor size and ctDNA measurements from the START-TKI study.

Related Experiment Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K
Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

7.5K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
  • Modeled tumor dynamics, including acquired resistance and explored exposure-response relationships.
  • Correlated baseline ctDNA (EGFR, TP53 variants) with tumor growth rates.

    • Main Results:

    • A population PK model adequately described erlotinib concentrations.
    • Acquired resistance, not primary resistance or heterogeneity, best explained tumor dynamics.
    • No significant exposure-response relationship for erlotinib was found within the studied range.
    • Higher baseline plasma EGFR mutation levels correlated with increased tumor growth rates.
    • Incorporating ctDNA measurements improved the model's fit, suggesting predictive value.

    Conclusions:

    • Baseline ctDNA levels, especially EGFR mutations, can predict tumor growth rates in NSCLC patients treated with erlotinib.
    • Quantitative ctDNA measurements show potential as a biomarker for predicting treatment response.
    • The developed model can inform the design of optimized treatment regimens to overcome resistance.